On this episode of Stock Movers:
- UnitedHealth (UNH) shares plunge after the company cut its annual forecast and reported its first earnings miss in over a decade. The company attributed the miss to rising medical costs, particularly in Medicare Advantage health plans and its Optum Health care delivery business, which were affected by Medicare payment changes.
- Eli Lilly (LLY) shares surge after data showed its experimental weight-loss pill worked as well as the Ozempic shot, bringing it one step closer to developing a needle-free alternative. The trial is one of several that Lilly is running to test the drug, called orforglipron, in diabetes, obesity and other related conditions like sleep apnea. Investors and analysts had expected it to work at least as well as Ozempic, the blockbuster diabetes shot from Novo Nordisk A/S.
- TSMC (TT) ADRs rise after the chipmaker forecast sales for the second quarter that beat the average analyst estimate. The company kept its growth outlook for 2025 on expectations of AI revenue doubling.
See omnystudio.com/listener for privacy information.
